Brief: Aligos Therapeutics Expects First-In-Human Studies In Coronavirus Therapeutic Program In H1 2023
08/12/2022 14:08
Dec 8 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS PRESENTS NONCLINICAL DATA FOR ITS
CORONAVIRUS THERAPEUTIC PROGRAM AT THE 2022 RESPI DART MEETING
* ALIGOS THERAPEUTICS INC- FIRST-IN-HUMAN STUDIES
ANTICIPATED TO
BEGIN IN H1 2023
Source text for Eikon: ID:nGNX527SxQ
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue